Medindia

X

AstraZeneca/Targacept's TC-5214 Will Become Decision Resources' Proprietary Clinical Gold Standard In 2013 Through 2018 For Treatment Resistant Depression

Monday, April 19, 2010 General News J E 4
Advertisement
Surveyed U.S. and European Physicians Indicate that Effect on Depressive Symptoms is the Most Important Drug Attribute They Consider When Prescribing for the Disorder, According to a New Report from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Hospira and Javelin Pharmaceuticals Enter Into Def...
S
Rhythmlink Obtains Medical Device License From Hea...